Vaxcyte, Inc. — Director's Dealing 2020

Jun 17, 2020

SEC Form 4/A — Form 4/A

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-11

Reporting Person: Abingworth LLP (10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-11	Stock option (right to buy)	$16.00	A	40000	Acquired	2030-06-10	Common Stock, $0.001 par value per share (40000)	Indirect

Footnotes

F1: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.

F2: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

F3: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.